Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Zimmer Biomet Holdings's Other Operating Expense for the
three
months ended in Mar. 2026 was €140 Mil.
Its Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was €582 Mil.
Zimmer Biomet Holdings's quarterly Other Operating Expense
increased
from Sep. 2025 (€150 Mil) to Dec. 2025 (€152 Mil) but then
declined
from Dec. 2025 (€152 Mil) to Mar. 2026 (€140 Mil).
Zimmer Biomet Holdings's annual Other Operating Expense
increased
from Dec. 2023 (€515 Mil) to Dec. 2024 (€565 Mil) and
increased
from Dec. 2024 (€565 Mil) to Dec. 2025 (€569 Mil).
Zimmer Biomet Holdings Other Operating Expense Related Terms
Zimmer Biomet Holdings Other Operating Expense Historical Data
* Premium members only.
The historical data trend for Zimmer Biomet Holdings's Other Operating Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zimmer Biomet Holdings Other Operating Expense Chart
Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)
Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.
Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €582 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Other Operating Expense of €582 Mil mean?
Zimmer Biomet Holdings (FRA:ZIM) has a Other Operating Expense of €582 Mil as of Mar. 2026. Other operating expenses that a company records on its income statement. View historical data on Zimmer Biomet Holdings and its competitors.
Is Zimmer Biomet Holdings' Other Operating Expense too high?
Zimmer Biomet Holdings' current Other Operating Expense is €582 Mil. Overall, Zimmer Biomet Holdings has a GF Score™ of 80/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Zimmer Biomet Holdings' Other Operating Expense compare to STE and PEN?
Zimmer Biomet Holdings' Other Operating Expense of €582 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Operating Expense for a Medical Devices & Instruments company?
A good Other Operating Expense depends on the Medical Devices & Instruments industry context. However, Other Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Operating Expense mean?
A high Other Operating Expense can signal that a stock is expensive relative to its fundamentals. Other operating expenses that a company records on its income statement. View historical data on Zimmer Biomet Holdings and its competitors. Zimmer Biomet Holdings's current Other Operating Expense is €582 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zimmer Biomet Holdings stock overvalued right now?
Based on GuruFocus' analysis, Zimmer Biomet Holdings (FRA:ZIM) is currently considered Modestly Undervalued. The stock's GF Value™ is €108.49, compared to a current price of €78.38 — trading 27.8% below its estimated fair value. The current Other Operating Expense is €582 Mil. Zimmer Biomet Holdings' overall GF Score™ is 80/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Operating Expense calculated?
Other Operating Expense is calculated from a company's financial statements. For Zimmer Biomet Holdings (FRA:ZIM), the current Other Operating Expense is €582 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zimmer Biomet Holdings (FRA:ZIM) Overvalued in 2026?
Based on GuruFocus' analysis, Zimmer Biomet Holdings stock appears to be undervalued.
The current stock price of €78.38 is trading 27.8% below its estimated GF Value™ of €108.49.
GuruFocus considers Zimmer Biomet Holdings to be Modestly Undervalued.
Key valuation signals for FRA:ZIM:
Other Operating Expense: €582 Mil
GF Value™: €108.49 vs. price of €78.38 (27.8% below fair value)
No single metric tells the full story. See the FRA:ZIM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two-thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.
80GF Score
Get the complete analysis for FRA:ZIM
Other Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:ZIM has been successfully added to your 
